Stephens Reaffirms “Equal Weight” Rating for Blueprint Medicines (NASDAQ:BPMC)
Stephens restated their equal weight rating on shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) in a report published on Tuesday,Benzinga reports. They currently have a $135.00 price objective on the biotechnology company’s stock, down from their prior price objective of $150.00. Several other equities research analysts also recently commented on BPMC. Morgan Stanley initiated […]
Stephens restated their equal weight rating on shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) in a report published on Tuesday,Benzinga reports. They currently have a $135.00 price objective on the biotechnology company’s stock, down from their prior price objective of $150.00. Several other equities research analysts also recently commented on BPMC. Morgan Stanley initiated […]
